stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Return on equity
Arcutis Biotherapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was 14.9%, up 24.2 percentage points from fiscal 2025 (−9.30%). Over the past ten years it has ranged from −175.8% (fiscal 2023) to 132.9% (fiscal 2018); the current reading is higher than 67% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −9.30% | 104.46 |
| FY2024 | −113.8% | 62.03 |
| FY2023 | −175.8% | (52.99) |
| FY2022 | −122.8% | (50.18) |
| FY2021 | −72.6% | 59.37 |
| FY2020 | −132.0% | (226.35) |
| FY2019 | 94.4% | (38.52) |
| FY2018 | 132.9% | 98.53 |
| FY2017 | 34.4% | — |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | 14.9% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −8.08% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| EWTX Edgewise Therapeutics, Inc. compare | −38.0% |
| DFTX Definium Therapeutics, Inc. compare | −64.1% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement